Yanyan Zheng

Xuzhou, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 11 publications

LGALS9 blockade augments vaccine-induced immune responses against prostate cancer.

LGALS9 blockade augments vaccine-induced immune responses against prostate cancer.

Journal: Journal for immunotherapy of cancer

Published: April 20, 2026

VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma.

VISTA neutralization by immunization reprograms immunosuppression and augments vaccine efficacy in renal carcinoma.

Journal: Journal for immunotherapy of cancer

Published: April 20, 2026

Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma.

Targeting Siglec-E facilitates tumor vaccine-induced antitumor immunity in renal carcinoma.

Journal: Journal for immunotherapy of cancer

Published: November 28, 2024

Co-immunization with IFI35 enhances the therapeutic effect of an adenovirus vaccine against renal carcinoma.

Co-immunization with IFI35 enhances the therapeutic effect of an adenovirus vaccine against renal carcinoma.

Journal: International journal of biological macromolecules

Published: September 22, 2024

Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors.

Adenovirus vaccine targeting kinases induces potent antitumor immunity in solid tumors.

Journal: Journal for immunotherapy of cancer

Published: August 12, 2024

Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity.

Therapeutic vaccine targeting dual immune checkpoints induces potent multifunctional CD8+ T cell anti-tumor immunity.

Journal: International immunopharmacology

Published: July 09, 2024

Adenovirus-assembled DC vaccine induces dual-targeting CTLs for tumor antigen and adenovirus to eradicate tumors.

Adenovirus-assembled DC vaccine induces dual-targeting CTLs for tumor antigen and adenovirus to eradicate tumors.

Journal: International immunopharmacology

Published: June 12, 2023

HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8+T cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma.

HMGB1/GPC3 dual targeting vaccine induces dendritic cells-mediated CD8+T cell immune response and elicits potential therapeutic effect in hepatocellular carcinoma.

Journal: iScience

Published: October 12, 2022

The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma.

The co-delivery of adenovirus-based immune checkpoint vaccine elicits a potent anti-tumor effect in renal carcinoma.

Journal: NPJ vaccines

Published: September 21, 2022

Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8+ T Cell Anti-Tumor Immunity in Hepatocellular Carcinoma.

Therapeutic Adenovirus Vaccine Combined Immunization with IL-12 Induces Potent CD8+ T Cell Anti-Tumor Immunity in Hepatocellular Carcinoma.

Journal: Cancers

Published: July 10, 2022

Atrophoderma of Pasini and Pierini in zosteriform distribution.

Atrophoderma of Pasini and Pierini in zosteriform distribution.

Journal: Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia

Published: October 30, 2015

Showing 1-11 of 11

Last Updated: 09/26/2026